Sandoz Canada has recalled its health product glimepiride, which is used to treat diabetes, over the mislabeling of boxes.
The mislabeling has occurred on outer carton of the product, which shows as containing 1mg tablets, while the blister package would contain 2mg tablets.
Mistake in labeling would lead to a greater than prescribed dose of glimepiride posing potentially serious risk to consumers by causing hypoglycemia.
The company has claimed to have received no reports of adverse reactions related to the problem either to Health Canada or to it.
Boxes recalled are said to come under the product lot number (L) DM5336.
Symptoms of hypoglycemia include weakness, drowsiness, blurred vision, headache, sweating and confusion.
Source:
http://pharmaproducts.packaging-business-review.com/news/sandoz-recalls-mislabeled-glimepiride-medicines-270114-4165898
